S
SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
TWSE:4119
Price:
83.1
TWD
0.48%
Market Closed
Market Cap:
9.9B
TWD
SCI Pharmtech Inc
Other Receivables
|
SCI Pharmtech Inc
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Other Receivables
NT$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Other Receivables
NT$276.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Other Receivables
NT$62.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
24%
|
CAGR 10-Years
8%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Other Receivables
NT$20.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-20%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Other Receivables
NT$268.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-8%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Other Receivables
NT$301m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
Intrinsic Value
58.86
TWD
Overvaluation 29%
S
See Also
What is SCI Pharmtech Inc's Other Receivables?
Other Receivables
0
TWD
0
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Other Receivables amounts to 0 TWD.
You don't have any saved screeners yet